VRX : Summary for Valeant Pharmaceuticals Interna - Yahoo Finance

U.S. Markets closed

Valeant Pharmaceuticals International, Inc. (VRX)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
16.18-0.40 (-2.41%)
At close: 4:01PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close16.58
Bid0.00 x
Ask0.00 x
Day's Range16.10 - 16.53
52 Week Range13.00 - 76.95
Avg. Volume14,655,042
Market Cap5.52B
PE Ratio (TTM)-2.46
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Forbes8 hours ago

    Q4 2016 Earnings Preview: What To Expect From Valeant Pharmaceuticals On Tuesday

    Valeant Pharmaceuticals is expected to earn $1.24/share on $2.35 billion in revenue. Meanwhile, the so-called Whisper number is $1.27. The Whisper number is the Street's unofficial view on earnings.

  • 24/7 Wall St.yesterday

    Top Biopharma Movers of the Past Week

    The health care sector was in trouble over the past year, under fire from congressional hearings and politicians on the campaign trail. However things look like they could be different in 2017.

  • Reuters2 days ago

    Sequoia Fund wins dismissal of lawsuit over huge Valeant stake

    A New York state judge has dismissed a lawsuit accusing the Sequoia Fund, known for its ties to Warren Buffett, of recklessly making a huge, disastrous investment in Valeant Pharmaceuticals International Inc (VRX.TO), causing billions of dollars of losses. Justice O. Peter Sherwood of the State Supreme Court in White Plains, New York, said Sequoia shareholders failed to show it would have been futile, prior to suing in January 2016, to demand that the mutual fund's directors step in to unwind the investment because of their alleged conflicts of interest.